A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

<p>Abstract</p> <p>Background</p> <p>The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. In contrast to earlier NNR...

Full description

Bibliographic Details
Main Authors: Johnson Barry C, Pauly Gary T, Rai Ganesha, Patel Disha, Bauman Joseph D, Baker Heather L, Das Kalyan, Schneider Joel P, Maloney David J, Arnold Eddy, Thomas Craig J, Hughes Stephen H
Format: Article
Language:English
Published: BMC 2012-12-01
Series:Retrovirology
Subjects:
HIV
Reverse transcriptase
Rilpivirine
Online Access:http://www.retrovirology.com/content/9/1/99

Internet

http://www.retrovirology.com/content/9/1/99

Similar Items